Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 63629-7524

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63629-7524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

A scientific plot showing the geometric mean ratio with 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of Desvenlafaxine across various renal and hepatic impairment levels and population subgroups by gender and age. The x-axis represents the change relative to reference, ranging from 0.5 to 3.5, with black squares indicating point estimates and horizontal lines showing confidence intervals.*

FDA Label Image

Figure2.jpg (Figure2)

A pharmacokinetic chart showing the geometric mean ratio with 90% confidence intervals for Cmax and AUC of desvenlafaxine when administered with ketoconazole, a CYP3A4 inhibitor. The x-axis represents the change relative to reference from 0.50 to 2.0, illustrating a 1.08 ratio for Cmax and 1.43 for AUC.*

FDA Label Image

Figure3.jpg (Figure3)

A forest plot chart illustrating the geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, AUCinf, AUClast) showing the effect of Desvenlafaxine (Pristiq) at various doses on the pharmacokinetics of interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole). The x-axis represents the change relative to reference, ranging from 0.5 to 2.5.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph comparing the estimated proportion of patients with relapse over time (days from randomization) between Desvenlafaxine 50 mg and placebo. The graph shows two lines: a solid line for Desvenlafaxine 50 mg and a dashed line for placebo, with relapse proportion on the vertical axis and time in days on the horizontal axis, covering up to 200 days.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph comparing the estimated proportion of patients with relapse over time (days from randomization) between Desvenlafaxine and placebo groups. The x-axis represents time up to 200 days, and the y-axis shows the proportion of relapse up to 50%. Desvenlafaxine is represented by a solid line and placebo by a dashed line.*

FDA Label Image

Image 04

Chemical structure of Desvenlafaxine, showing its molecular composition with aromatic ring, hydroxyl groups, and carboxylic acid groups as part of the compound.*

FDA Label Image

Label (Lbl636297524)

Label for Desvenlafaxine ER 25 mg extended-release tablet by Bryant Ranch Prepack, comparing to Pristiq 25 mg tablet by West-Ward Columbus Inc. The label includes storage instructions at 20°-25°C (68°-77°F), a warning to keep drugs out of reach of children, a barcode, lot number 1523487, and NDC 63629-7524-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.